News

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD). It has been recommended

EffRx Pharmaceuticals has received marketing authorisation from Swissmedic for Bronchitol to treat cystic fibrosis (CF) in adults and in children aged six years and above. Developed by Australian

Novavax has completed the rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its Covid-19 vaccine candidate, NVX-CoV2373. The company has submitted all

SNX281 is Stingthera’s small molecule agonist of the Stimulator of Interferon Genes (STING) protein. An anti-programmed death receptor-1 (anti-PD-1) therapy, Keytruda is a registered trademark of Merck &

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies. Under the deal, Novartis gets the sole rights

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics. As part of the collaboration, the companies will discover, develop, and

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Pfizer-BioNTech’s Covid-19 vaccine for children aged 5 to 11 years. The 10-µg vaccine doses

Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast

Pfizer and its partner BioNTech have announced that the US government has purchased additional paediatric doses of their Covid-19 vaccine, as it prepares for paediatric vaccinations. Under the